Shares of Intrexon Corp (NYSE:XON) have received a consensus recommendation of “Hold” from the nine analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $38.50.
Several equities analysts have recently commented on XON shares. Zacks Investment Research downgraded shares of Intrexon from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Northland Securities restated a “buy” rating and issued a $21.00 price target on shares of Intrexon in a research report on Friday, November 10th. Stifel Nicolaus boosted their price target on shares of Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, November 10th. ValuEngine cut shares of Intrexon from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Finally, Bank of America reduced their price target on shares of Intrexon from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th.
In other Intrexon news, CEO Randal J. Kirk purchased 1,000,000 shares of Intrexon stock in a transaction that occurred on Friday, January 19th. The shares were bought at an average price of $12.50 per share, for a total transaction of $12,500,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 56.30% of the company’s stock.
Intrexon (NYSE XON) traded up $0.51 during mid-day trading on Tuesday, hitting $13.16. 711,843 shares of the stock traded hands, compared to its average volume of 2,286,994. Intrexon has a 1 year low of $10.26 and a 1 year high of $26.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85. The stock has a market capitalization of $1,640.00, a P/E ratio of -11.67 and a beta of 1.40.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.